HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA. PROMACTA (eltrombopag) tablets, for oral use Initial U.S. Approval: 2024 . WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C
by H Al‐Samkari 2024 Cited by 77Nplate (romiplostim) [prescribing information]. Thousand Oaks Promacta (eltrombopag) [prescribing information]. Research Triangle
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA. PROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2024 WARNING: RISK FOR HEPATIC DECOMPENSATION IN
Promacta Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October. 2024. Available at
HIGHLIGHTS OF PRESCR IBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA. PROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2024 . WARNING: RISK FOR HEPATIC DECOMPENSATION IN
April 2024. 3 Nplate prescribing information. Amgen. February 2024. 4 Promacta prescribing information. Novartis. March 2024. 5 Tavalisse prescribing
Eltrombopag (Promacta) is a thrombopoietin receptor agonist. FDA Promacta Prescribing Information. Research Triangle Park, NC
Promacta (eltrombopag) Prescribing and Labeling Information . Content current as of: . Postmarket Drug Safety Information for Patients and Providers
Promacta was administered in combination with pegylated interferon and ribavirin per their respective prescribing information for up to 48
Comments
SHOULD BE:
Andy had literally simply RELAYED all the various information.